Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1987 Sep;71(3):153-7.

Bronchodilator effect of Aerochamber and Inspirease in comparison with metered dose inhaler

N Crimi  1 , F Palermo, B Cacopardo, C Vancheri, R Oliveri, B Palermo, A Mistretta
Affiliations
  • PMID: 3678415
Clinical Trial

Bronchodilator effect of Aerochamber and Inspirease in comparison with metered dose inhaler

N Crimi et al. Eur J Respir Dis. 1987 Sep.

Abstract

This trial was performed in a randomized double-blind manner on four different days in 13 asthmatic patients in order to compare the bronchodilator efficacy of two different inhalation devices, Inspirease (IP) and Aerochamber (AC), to the conventional metered dose inhaler (MDI). The results showed that clenbuterol determined a significant FEV1 increase inhaled either via MDI or via IP and AC. IP caused a greater bronchodilatation than AC, 30 min after clenbuterol administration. IP caused a greater mean increase (P less than 0.05) in FEV1 than the MDI at all time intervals; AC provided an improvement in bronchodilator response over directly administered MDI. Such responses are only marginally clinically relevant when patients use MDI correctly. These devices are mainly indicated in patients with poor hand-lung coordination.

PubMed Disclaimer